Thinking Beyond Symptoms: The Blind Spot in the Treatment of Anxiety

Defining anxiety as a disorder may, from the outset, reflect a flawed conceptual framework. From a neurobiological perspective, anxiety constitutes one of the most fundamental and adaptive response systems developed by the organism to detect and respond to threats. Centered around the amygdala, this system rapidly evaluates environmental stimuli and prepares the organism for potential danger by triggering physiological responses such as increased heart rate, elevated muscle tension, and the release of stress hormones. In this sense, anxiety is not a dysfunction, but a finely tuned alarm mechanism essential for survival. However, in the context of modern life characterized by persistent and often abstract threats, this system may shift from an acute and adaptive response to a chronic and distressing experience. At this point, approaching anxiety merely as a symptom to be suppressed risks overlooking a more fundamental issue.

Psychopharmacology In Anxiety: Effects and Limitations

Given the neurobiological basis of anxiety, psychopharmacological interventions primarily exert their effects at the level of neurotransmitter systems. The most commonly used pharmacological treatments include selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and benzodiazepines. While SSRIs and SNRIs increase the availability of serotonin and norepinephrine in the synaptic cleft, thereby contributing to mood regulation, benzodiazepines enhance inhibitory signaling via gamma-aminobutyric acid (GABA), suppressing central nervous system activity.

The shared mechanism underlying these interventions lies in reducing the intensity of the organism’s response to perceived threats. In other words, the goal is not to eliminate the anxiety system altogether, but to lower its reactivity. This allows the physiological and cognitive experience of anxiety to become more manageable. However, the effects of psychopharmacological treatments are largely limited to modulating how this response manifests. Rather than directly altering the environmental, cognitive, or behavioral processes that give rise to anxiety, these interventions regulate the neurobiological response to those processes. This distinction is critical: the intervention does not eliminate the system itself but reshapes its output.

The Blind Spot: Regulating The Symptom While Anxiety Is Being Produced

Although psychopharmacological interventions play an important role in reducing the intensity and impact of anxiety, their limitations must be carefully considered. These interventions primarily regulate the intensity of the organism’s response to perceived threats, rather than directly addressing the processes that generate that response. In other words, while the physiological and emotional outputs of anxiety may be brought under control, the cognitive, environmental, and behavioral dynamics that produce these outputs often remain unchanged.

This becomes particularly relevant when considering why anxiety tends to manifest in chronic and recurring forms. The structure of modern life—marked by persistent uncertainty, continuous stimulation, and heightened performance demands—keeps the threat detection system in a prolonged state of activation. Under such conditions, anxiety ceases to be an adaptive response to a specific situation and instead becomes a continuously produced experience. As a result, interventions that focus solely on reducing the intensity of this experience tend to address its visible outcomes rather than its underlying causes.

In this context, a key issue often overlooked in the treatment of anxiety is the mismatch between the level of intervention and the level at which the problem emerges. While interventions are typically implemented at the neurochemical level, the mechanisms that sustain anxiety continue to operate at cognitive, behavioral, and environmental levels. This mismatch does not render psychopharmacology ineffective; rather, it limits its sufficiency as a standalone approach.

Reducing Anxiety Or Transforming The System That Produces It?

Treating anxiety solely as an experience to be reduced renders the context in which it emerges largely invisible. Yet anxiety is often not a sign of dysfunction, but a consistent response to the conditions in which the organism exists. The issue, therefore, is not merely to regulate the intensity of this response, but to understand why it is repeatedly produced. Anxiety frequently reflects the individual’s ongoing interaction with their environment, and unless this relationship changes, the response is likely to reappear in different forms.

The structure of modern life plays a decisive role in this process. Persistent stimulation, uncertainty, performance pressure, and uncontrollable variables keep the threat detection system chronically activated. In such an environment, anxiety becomes not an exception, but a systematic outcome. This raises a critical question: if the system continuously produces anxiety under these conditions, to what extent is reducing its intensity sufficient?

Psychopharmacological interventions can enhance functionality by reducing the intensity of this experience and are indispensable in clinical practice. However, they primarily regulate the response itself rather than the context that generates it. Consequently, the persistence of anxiety is shaped not only by neurochemical processes but also by environmental, cognitive, and behavioral structures. As long as this context remains unchanged, anxiety is likely to persist—not merely as a suppressed experience, but as a process that re-emerges in different forms.

A more comprehensive approach, therefore, requires not the elimination of anxiety, but an understanding of the conditions under which it is repeatedly produced. Otherwise, intervention risks becoming not a solution to anxiety, but a mechanism that obscures the very conditions in which it arises.